Patient attitudes and preferences about expanded noninvasive prenatal testing

Marie-Line Dubois; Patricia D Winters; Marc-André Rodrigue; Jean Gekas

doi:10.3389/fgene.2023.976051

Patient attitudes and preferences about expanded noninvasive prenatal testing

Front Genet. 2023 Apr 18:14:976051. doi: 10.3389/fgene.2023.976051. eCollection 2023.

Authors

Marie-Line Dubois¹, Patricia D Winters², Marc-André Rodrigue³, Jean Gekas^{1

3}

Affiliations

¹ Faculty of Medicine, Laval University, Quebec City, QC, Canada.
² Illumina, Inc., San Diego, CA, United States.
³ CHU de Quebec Research and Mother and Child Center, Department of Medical Genetics, University Hospital of Quebec, Laval University, Quebec City, QC, Canada.

Abstract

Introduction: Noninvasive prenatal testing (NIPT) using cell-free DNA (cfDNA) is typically carried out to screen for common fetal chromosomal anomalies, with the option to screen for a wider range of chromosomal changes (expanded NIPT) becoming increasingly available. However, little is known about pregnant patients' attitudes and preferences regarding expanded NIPT. Methods: To address this gap, we surveyed general-risk patients having first-tier cfDNA screening at a private prenatal clinic on their expectations for expanded NIPT. Patients were asked questions regarding their current pregnancy and previous pregnancy history, their opinions on fetal DNA screenings during pregnancy and incidental findings, information and opinions on financial resources for NIPT, as well as socio-cultural questions to determine patient demographics. Results: Of the 200 survey participants, the majority were educated, self-reported as white, had a higher than average income, and reported no aneuploidy risk factors. When asked what information they would like to receive from cfDNA screening, the vast majority of participants wanted all information available that could have an immediate impact on fetal health (88%) or an immediate impact on infant health from birth (82%). Many participants also wanted information that could have a future impact on the child's health or an immediate or future impact on the pregnant woman's own health. Most participants wanted information about the sex of fetus (86%) and common trisomies (71%), with almost half of participants desiring information about rare autosomal aneuploidies and/or all genetic information that may affect the baby. In addition, participants were found to be comfortable screening for conditions that are well-known, influence care during pregnancy, and are treatable. Finally, while most respondents either had insurance coverage for NIPT or were able to afford NIPT out of pocket, the majority of our participants felt that expanded NIPT should be either free for everyone or for those considered high risk. Discussion: Our findings suggest that with appropriate pre-test counseling, pregnant patients may choose NIPT for an expanding list of conditions.

Keywords: aneuploidy; cell-free DNA; incidental findings; informed consent; noninvasive prenatal testing; patient preference; surveys and questionnaires.